Search Results - "Fargeot, P"

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial by Fléchon, A., Pouessel, D., Ferlay, C., Perol, D., Beuzeboc, P., Gravis, G., Joly, F., Oudard, S., Deplanque, G., Zanetta, S., Fargeot, P., Priou, F., Droz, J.P., Culine, S.

“…In the evolution of metastatic castration-resistant prostate cancer (mCRPC), patients present visceral metastases with or without neuroendocrine…”
Get full text

Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial by BIGANZOLI, L, CUFER, T, LOHRISCH, C, PICCART, M. J, BRUNING, P, COLEMAN, R, DUCHATEAU, L, CALVERT, A. H, GAMUCCI, T, TWELVES, C, FARGEOT, P, EPELBAUM, R

“…To compare the efficacy and tolerability of the combination of doxorubicin and paclitaxel (AT) with a standard doxorubicin and cyclophosphamide (AC) regimen as…”
Get full text

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results by Fumoleau, P., Roché, H., Kerbrat, P., Bonneterre, J., Romestaing, P., Fargeot, P., Namer, M., Monnier, A., Montcuquet, P., Goudier, M.-J., Luporsi, E.

“…Background: The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients…”
Get full text

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer by Efficace, F, Biganzoli, L, Piccart, M, Coens, C, Van Steen, K, Cufer, T, Coleman, R.E, Calvert, H.A, Gamucci, T, Twelves, C, Fargeot, P, Bottomley, A

“…The potential value of baseline health-related quality-of-life (HRQOL) and clinical factors in predicting prognosis was examined using data from an…”
Get full text

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure by BONNETERRE, J, ROCHE, H, MONNIER, A, GUASTALLA, J. P, NAMER, M, FARGEOT, P, ASSADOURIAN, S

“…This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of…”
Get full text

Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial by Roché, H., Kerbrat, P., Bonneterre, J., Fargeot, P., Fumoleau, P., Monnier, A., Clavère, P., Goudier, M.-J., Chollet, P., Guastalla, J.-P., Serin, D.

“…Background: The purpose of this study was to determine optimal adjuvant therapy between complete hormonal blockade in premenopausal patients with hormone…”
Get full text

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group by Campone, M., Roché, H., Kerbrat, P., Bonneterre, J., Romestaing, P., Fargeot, P., Namer, M., Monnier, A., Montcuquet, P., Goudier, M.-J., Fumoleau, P.

“…Background: The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast…”
Get full text

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO) by Rousseau, F, Retornaz, F, Joly, F, Esterni, B, Abadie-Lacourtoisie, S, Fargeot, P, Luporsi, E, Servent, V, Laguerre, B, Brain, E, Geneve, J

“…Abstract Background Elderly metastatic cancer patients typically have short life expectancy and frequently suboptimal treatment. Goals of therapy should…”
Get full text

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer by Biron, P, Durand, M, Roché, H, Delozier, T, Battista, C, Fargeot, P, Spaeth, D, Bachelot, T, Poiget, E, Monnot, F, Tanguy, M L, Curé, H

“…Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on…”
Get full text

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial by Romieu, G, Clemens, M, Mahlberg, R, Fargeot, P, Constenla, M, Schütte, M, Easton, V, Skacel, T, Bacon, P, Brugger, W

“…Abstract This randomized phase 2 study explored the feasibility of delivering four to six cycles of the dose-intensified regimen FEC-100 (5-fluorouracil,…”
Get full text

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials by Namer, M., Fargeot, P., Roché, H., Campone, M., Kerbrat, P., Romestaing, P., Monnier, A., Luporsi, E., Montcuquet, P., Bonneterre, J.

“…Background: The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three…”
Get full text

Hepatoid adenocarcinoma of the lung : Report of a case of an unusual α-fetoprotein-producing lung tumor by ARNOULD, L, DROUOT, F, FARGEOT, P, BERNARD, A, FOUCHER, P, COLLIN, F, PETRELLA, T

“…We report on a rare tumor of the lung characterized by its morphologic hepatoid features and alpha-fetoprotein production. This unusual neoplasm arose in the…”
Get full text

Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer : French Adjuvant Study Group 09 trial by KERBRAT, P, ROCHE, H, GAUDIER, M.-J, AUDHUY, B, SIMON, H, MONTCUQUET, P, EYMARD, J.-C, WALTER, S, CLAVERE, P, GUASTALLA, J.-P, BONNETERRE, J, VEYRET, C, LORTHOLARY, A, MONNIER, A, FUMOLEAU, P, FARGEOT, P, NAMER, M, CHOLLET, P

“…The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg…”
Get full text

A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer by Fiedler, W., Tchen, N., Bloch, J., Fargeot, P., Sorio, R., Vermorken, J.B., Collette, L., Lacombe, D., Twelves, C.

“…Sabarubicin (MEN-10755), a new synthetic anthracycline analogue, was evaluated for safety and efficacy in a multicentre phase II study in patients with…”
Get full text

Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment by the French Epirubicin Study Group

“…To determine whether the duration and the dose of epirubicin modify the long-term outcome of patients with metastatic breast cancer (MBC). Four hundred…”
Get full text

Germ cell testicular tumors: understanding the kinetics of serum human chorionic gonadotropin during chemotherapy by Riedinger, J-M, Eche, N, Fargeot, P

“…The analysis of longitudinal series of tumour markers during chemotherapy in patients with germ cells tumors is not easy. The purpose of this work is to…”
Get more information

Germ cell testicular tumors: understanding the kinetics of serum alpha-fetoprotein (AFP) during chemotherapy by Riedinger, J-M, Eche, N, Chevreau, C, Fargeot, P

“…The analysis of longitudinal series of tumour markers during chemotherapy in patients with germ cells tumors is not easy. The purpose of this work is to…”
Get more information

Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer : a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) by LAPLANCHE, A, ALZIEU, L, DELOZIER, T, BERLIE, J, VEYRET, C, FARGCOT, P, LUBOINSKI, M, LACOUR, J

“…With a median follow-up of 14 years, the combination of polyadenylic-polyuridylic acid plus locoregional radiotherapy (257 patients) has significantly improved…”
Get full text

Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer by DEPORTE-FETY, R, SIMON, N, FUMOLEAU, P, CAMPONE, M, KERBRAT, P, BONNETERRE, J, FARGEOT, P, URIEN, S

“…To develop a population pharmacokinetic model of vinorelbine administered by short intravenous infusion in metastatic breast cancer patients. Vinorelbine was…”
Get full text

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration by Misset, J L, di Palma, M, Delgado, M, Plagne, R, Chollet, P, Fumoleau, P, Le Mevel, B, Belpomme, D, Guerrin, J, Fargeot, P, Metz, R, Ithzaki, M, Hill, C, Mathé, G

“…To determine the long-term impact on disease-free survival (DFS) and overall survival (OS) of adjuvant anthracycline-based chemotherapy, when prospectively…”
Get more information